US Stock MarketDetailed Quotes
DNTH Dianthus Therapeutics
- 23.450
- +1.110+4.97%
Close Nov 25 16:00 ET
694.05MMarket Cap-10262P/E (TTM)
24.295High22.850Low338.20KVolume22.850Open22.340Pre Close7.98MTurnover2.71%Turnover RatioLossP/E (Static)29.60MShares33.77052wk High2.05P/B292.76MFloat Cap6.58052wk Low--Dividend TTM12.48MShs Float336.000Historical High--Div YieldTTM6.47%Amplitude5.136Historical Low23.594Avg Price1Lot Size
About Dianthus Therapeutics Company
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.
Company Profile
SymbolDNTH
Company NameDianthus Therapeutics
Listing DateJun 21, 2018
Founded2015
CEOMr. Marino Garcia
MarketNASDAQ
Employees53
Fiscal Year Ends12-31
Address7 Times Square,43rd Floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10036
Phone1-929-999-4055
Websitehttp://dianthustx.com
Company Executives
- Name
- Position
- Salary
- Marino Garcia
- President, Chief Executive Officer and Director
- --
- Dr. Simrat Randhawa, M.D.
- Chief Medical Officer
- --
- Edward G. Carr
- Chief Accounting Officer
- --
- Ryan Savitz
- Chief Financial Officer, Chief Business Officer and Treasurer
- --
- Adam M. Veness
- Senior Vice President, General Counsel and Secretary
- --
- Leon O. Moulder, Jr
- Chairman of the Board
- --
- Dr. Steven Joseph Romano, M.D.
- Director
- --
- Dr. Jonathan Violin, M.B.A.,PhD
- Director
- --
- Alison F. Lawton
- Independent Director
- --
- Paula Soteropoulos
- Independent Director
- --
- Anne M. McGeorge
- Independent Director
- --
- Tomas Kiselak
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
